DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95% PFS at four years in transplant-eligible 1L multiple myeloma patients who achieved sustained MRD negativity June 10, 2025
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in RRMM patients June 10, 2025
BMJ Publishes results from OptiTROP-Lung03 trial of sacituzumab tirumotecan (sac-TMT) vs docetaxel in patients with previously treated EGFR-mutant NSCLC June 10, 2025
Positive Topline Efficacy Results Reported from Ph 1B/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Mets (MB-107) June 10, 2025
Efti with Radiotherapy & KEYTRUDA Meets Primary Endpoint in Ph 2 for Soft Tissue Sarcoma June 3, 2025
Ivonescimab + Chemo Demonstrates Statistically Significant PFS Improvement and numerical OS improvement in topline data in EGFRm NSCLC after EGFR TKI June 3, 2025
Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA+ve metastatic HSPC June 3, 2025
Positive Results from Ph 3 TALENTACE Study of Tecentriq and Avastin for Unresectable HCC announced May 27, 2025
Trodelvy Demonstrates Significant PFS Improvement in 1L Metastatic TNBC Patients Not Candidates for Checkpoint Inhibitors in ASCENT-03 trial May 27, 2025
FAILED TRIAL: GALAXIES Lung-201 of Belrestotug + Dostarlimab in 1L PD-L1 High NSCLC Patients did not meet PFS endpoint May 21, 2025
Ten-year APHINITY data show Perjeta-based regimen reduced the risk of death by 17% in people with HER2+ve early-stage breast cancer May 21, 2025
Ph 3 Trial of Disitamab Vedotin in 1L HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma meets Primary Endpoints of PFS and OS May 21, 2025
Ph 3 KEYNOTE-B96 Trial Met Primary PFS Endpoint in Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers May 21, 2025
Updated Ph 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the treatment of NHL Announced May 21, 2025
Two Ph 2 trials of Samuraciclib + SERDs in HR+ve Advanced Breast Cancer demonstrate extended PFS in patients without TP53 mutations or without liver mets May 21, 2025
Enhertu followed by THP before surgery showed statistically significant pCR improvement high-risk HER2-positive early-stage breast cancer patients in DESTINY-Breast11 Ph 3 trial May 13, 2025
Statistically Significant Topline Results from Global Ph 2 Trial of Elraglusib in 1L Treatment of Metastatic Pancreatic Cancer Announced May 13, 2025
